Therefore, BACE-1 is considered a primary drug target for reducing early Aβ production in AD, and methods to inhibit the BACE-1 catalysis of Aβ aggregation have become an effective strategy for treating AD patients, demonstrating significant therapeutic potential. The gene discussed is BACE1; the disease is Alzheimer disease.